BPC-157

BPC-157 is a pentadecapeptide fragment (15 amino acids) derived from human gastric juice protein BPC (Body Protection Compound). It exerts its effects primarily through upregulation of vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), driving angiogenesis — the formation of new blood vessels — at sites of tissue injury.

Beyond angiogenesis, BPC-157 modulates the nitric oxide (NO) system, interacts with the dopaminergic and serotonergic neurotransmitter pathways, and accelerates fibroblast migration and collagen deposition. In rodent models, it has demonstrated accelerated healing of transected Achilles tendons, gastric ulcers, and ligamentoous injuries. The peptide also exhibits pronounced gastroprotective effects through stabilization of the gut mucosal barrier.

Its short systemic half-life (~4 hours) necessitates daily research administration protocols to maintain steady-state tissue concentrations. Local injection near the site of injury appears to produce higher local tissue levels than systemic administration in animal models.

BPC-157 was first isolated and characterized at the University of Zagre in the early 1990s by a research group led by Prof. Predrag Sikirić. Early research focused on its gastric cytoprotective properties, leading to its classification as a "Body Protection Compound." Over the subsequent three decades, more than 200 peer-reviewed publications have documented its effects across multiple tissue types and injury models.

The compound has been extensively studied in rodent models of musculosceletal injury, inflammatory bowel disease, and central nervous system trauma. No formal human clinical trials have been completed as of 2026, though case-report literature and anecdotal research data have driven significant interest in the biohacking and regenerative-medicine communities.

Lypophilized BPC-157 is stable at -20°C for >24 months. It is one of the more robust peptides in storage; brief room-temperature exposure during shipping does not significantly degrade the compound. Store vials in a dark, dry environment.

After reconstitution with bacteriostatic water, BPC-157 remains stable at 2–8°C for 21–28 days. Some research protocols recommend aliquoting the reconstituted solution into sterile single-use vials and freezing at -20°C for extended storage (up to 90 days), though a single freeze-thaw cycle should be observed. Do not refreeze after thawing.